List of Yutiq drug patents

Yutiq is owned by Eyepoint Pharms.

Yutiq contains Fluocinolone Acetonide.

Yutiq has a total of 2 drug patents out of which 0 drug patents have expired.

Yutiq was authorised for market use on 12 October, 2018.

Yutiq is available in implant;intravitreal dosage forms.

Yutiq can be used as a method of injecting an implant.

The generics of Yutiq are possible to be released after 12 January, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871241 EYEPOINT PHARMS Injectable sustained release delivery devices
Aug, 2027

(4 years from now)

US7998108 EYEPOINT PHARMS Injector apparatus and method of use
Jan, 2028

(4 years from now)

Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient

Market Authorisation Date: 12 October, 2018

Treatment: A method of injecting an implant

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in